Oxurion NV
XBRU:OXUR

Watchlist Manager
Oxurion NV Logo
Oxurion NV
XBRU:OXUR
Watchlist
Price: 0.28 EUR Market Closed
Market Cap: 374.2k EUR
Have any thoughts about
Oxurion NV?
Write Note

Oxurion NV
Operating Income

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Oxurion NV
Operating Income Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Operating Income CAGR 3Y CAGR 5Y CAGR 10Y
Oxurion NV
XBRU:OXUR
Operating Income
-€12m
CAGR 3-Years
25%
CAGR 5-Years
21%
CAGR 10-Years
N/A
M
MDxHealth SA
NASDAQ:MDXH
Operating Income
-$36.1m
CAGR 3-Years
-11%
CAGR 5-Years
-3%
CAGR 10-Years
-4%
Galapagos NV
AEX:GLPG
Operating Income
-€213.9m
CAGR 3-Years
-4%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Celyad Oncology SA
XBRU:CYAD
Operating Income
-€7.8m
CAGR 3-Years
20%
CAGR 5-Years
26%
CAGR 10-Years
N/A
No Stocks Found

Oxurion NV
Glance View

Market Cap
343.7k EUR
Industry
Biotechnology

Oxurion NV is a biopharmaceutical company, which engages in developing and commercializing medicines for the treatment of vitreo retinal diseases. The company is headquartered in Heverlee, Vlaams-Brabant and currently employs 42 full-time employees. The company went IPO on 2006-07-07. Its lead product, JETREA (ocriplasmin), has been approved by the United States Food and Drug Administration for the treatment of symptomatic vitreomacular adhesion (VMA) and was launched in January 2013. Oxurion partners with Alcon (Novartis) for the commercialization of JETREA outside the United States. In Europe, JETREA is approved for the treatment of vitreomacular traction (VMT), including when associated with macular hole of diameter less than or equal to 400 microns, which was launched in the United Kingdom and Germany. In addition, it also explores anti-PIGF (Placental Growth Factor), also referred to as TB-403, for the treatment of ophthalmic and oncology indications. The firm is active domestically, as well as operates through offices located in the United States and Ireland.

OXUR Intrinsic Value
0.78 EUR
Undervaluation 64%
Intrinsic Value
Price

See Also

What is Oxurion NV's Operating Income?
Operating Income
-12m EUR

Based on the financial report for Dec 31, 2023, Oxurion NV's Operating Income amounts to -12m EUR.

What is Oxurion NV's Operating Income growth rate?
Operating Income CAGR 5Y
21%

Over the last year, the Operating Income growth was 45%. The average annual Operating Income growth rates for Oxurion NV have been 25% over the past three years , 21% over the past five years .

Back to Top